Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
This story is reported by Yahoo Finance. Read what other outlets are saying below, then open the original report for full details.